• E-mail
  • Save
28 Stories on Fosamax
Search this topic

What are good options for osteoporosis meds?

I am a healthy and fit 55-year-old woman. My bone density test showed that I needed to be supplemented. I cannot take hormones as I had a blood clot, so the doctor prescribed Fosamax. I had awful side effects: muscle pain, joint pain, etc. He has now prescribed Forteo. Is this a good alternative?

What should I consider before having uterus, ovaries removed?

I have had painful periods for the past couple of years and have also had ovarian cysts. I had a couple of larger cysts removed about five years ago and was told I had endometriosis at that time. I continue to have pain and now have been told I have a 7 cm cyst on the right ovary. My doctor recommends removing both ovaries and the uterus. I'm just researching the pros and cons. Was wondering if there are any major issues I should be concerned about if I had the uterus and both ovaries removed. I am 42 and do not plan to have children. Given the history of pain and previous cysts, is it a good idea to go ahead and remove everything? Thanks for your time. Melissa

Fosamax may increase risk of irregular heartbeat

Women who have used the bone-building drug Fosamax are nearly twice as likely to develop the most common kind of chronically irregular heartbeat as those who have never used it. Patients, especially those with family history of heart problems, should talk to their doctor about whether the drug is the appropriate option for them. The study was published in the Archives of Internal Medicine in April 2008.

CNNMoney: Merck's Fosamax gets the ax

Merck & Co. bids adieu to its bone disease blockbuster drug on Wednesday, when the patent finally runs out on Fosamax.

CNNMoney: Big Pharma's leaky pipeline

After the latest round of mixed earnings from the biggest players in pharma and biotech, companies are hampered by a frustrating dynamic: a product mix that isn't strong enough to match an exodus of blockbusters.

CNNMoney: Amgen earnings, sales beat forecast

Biotech Amgen on Thursday reported an increase in earnings and a decrease in sales for the fourth quarter, beating Wall Street's forecast.

Fortune: Amgen's science doesn't guarantee profits

Amgen just can't get a break these days.

CNNMoney: Merck earnings guidance fails to inspire

Merck failed to excite investors with its financial guidance for 2007 and 2008, causing a temporary stock drop, but analysts were reluctant to condemn the drugmaker.

Fortune: Update: Merck recovers from Vioxx

What we said In "Merck Is on the Mend" (Feb. 5), we recommended a second look at the pharma giant, which was recovering from the low it reached in 2004 amid the Vioxx debacle. We mentioned that Merck was winning approvals for a host of new drugs, including cervical-cancer vaccine Gardasil. We cited Bear Stearns analyst John Boris's year-end price target of $53.

CNNMoney: Merck tops forecasts

Merck posted a 62 percent increase in its third-quarter profit Monday, as the drugmaker's revenues increased by double digits, while lower administration and overhead costs offset more spending on research and development.

Advertisement
Quick Job Search :
keyword(s):
enter city: